Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 2
2003 4
2004 5
2005 2
2006 1
2007 7
2008 11
2009 9
2010 11
2011 10
2012 21
2013 12
2014 19
2015 6
2016 8
2017 7
2018 4
2019 6
2020 4
2021 7
2022 2
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8. J Nucl Med. 2016. PMID: 26449837 Free article. Clinical Trial.
Immuno-imaging using nanobodies.
Vaneycken I, D'huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T. Vaneycken I, et al. Among authors: lahoutte t. Curr Opin Biotechnol. 2011 Dec;22(6):877-81. doi: 10.1016/j.copbio.2011.06.009. Epub 2011 Jul 2. Curr Opin Biotechnol. 2011. PMID: 21726996 Review.
Immunogenicity Risk Profile of Nanobodies.
Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, Elkrim Y, Devoogdt N, Caveliers V, Lahoutte T, Muyldermans S, Breckpot K, Keyaerts M. Ackaert C, et al. Among authors: lahoutte t. Front Immunol. 2021 Mar 9;12:632687. doi: 10.3389/fimmu.2021.632687. eCollection 2021. Front Immunol. 2021. PMID: 33767701 Free PMC article.
Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
Gondry O, Caveliers V, Xavier C, Raes L, Vanhoeij M, Verfaillie G, Fontaine C, Glorieus K, De Grève J, Joris S, Luyten I, Zwaenepoel K, Vandenbroucke F, Waelput W, Thyparambil S, Vaneycken I, Cousaert J, Bourgeois S, Devoogdt N, Goethals L, Everaert H, De Geeter F, Lahoutte T, Keyaerts M. Gondry O, et al. Among authors: lahoutte t. J Nucl Med. 2024 Feb 1;65(2):178-184. doi: 10.2967/jnumed.123.266254. J Nucl Med. 2024. PMID: 38302159 Free PMC article. Clinical Trial.
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, Breckpot K, Lecocq Q, Decoster L, Fontaine C, Schallier D, Aspeslagh S, Vaneycken I, Raes G, Van Ginderachter JA, Lahoutte T, Caveliers V, Keyaerts M. Gondry O, et al. Among authors: lahoutte t. J Nucl Med. 2023 Sep;64(9):1378-1384. doi: 10.2967/jnumed.122.264853. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474271 Free PMC article. Clinical Trial.
Bioluminescence imaging: looking beyond the light.
Keyaerts M, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. Trends Mol Med. 2012 Mar;18(3):164-72. doi: 10.1016/j.molmed.2012.01.005. Epub 2012 Feb 8. Trends Mol Med. 2012. PMID: 22321645 Review.
145 results